ERBB2 and breast cancer: Pathologic complete response (pCR) following NACT is a robust prognostic biomarker for excellent long-term outcomes at the individual patient level, but pCR rates are substantially low (~5–15%) among patients with HR+/HER2- BC [10, 11].